Eidos therapeutics Review

About Eidos therapeutics

Eidos Therapeutics: Addressing Unmet Needs in Transthyretin Amyloidosis

Eidos Therapeutics is a clinical stage biopharmaceutical company that is dedicated to developing innovative therapies for diseases caused by transthyretin amyloidosis (ATTR). The company was founded in 2013 and has since been working tirelessly to address the growing unmet need in this area.

Transthyretin amyloidosis is a rare and progressive disease that affects multiple organs, including the heart, nerves, and digestive system. It occurs when abnormal proteins called amyloids build up in the body's tissues and organs, leading to organ dysfunction and failure. There are two types of ATTR: hereditary ATTR (hATTR) and wild-type ATTR (wtATTR). hATTR is caused by genetic mutations that affect the production of transthyretin protein, while wtATTR occurs spontaneously without any known genetic cause.

Despite being a rare disease, ATTR has become an increasingly important area of focus for drug development due to its high morbidity rate. Currently available treatments only provide symptomatic relief but do not address the underlying cause of the disease. This is where Eidos Therapeutics comes in.

The company's lead product candidate is AG10, an oral small molecule designed to stabilize transthyretin protein and prevent its misfolding into amyloids. AG10 has shown promising results in preclinical studies as well as Phase 1 clinical trials. In these trials, AG10 was well-tolerated with no serious adverse events reported.

Eidos Therapeutics recently completed enrollment for its Phase 3 clinical trial of AG10 called ATTRibute-CM. This trial aims to evaluate the safety and efficacy of AG10 compared to placebo in patients with hATTR cardiomyopathy – a form of hATTR that affects the heart – who have not yet received treatment with TTR stabilizers or gene-silencing therapies.

In addition to AG10, Eidos Therapeutics also has other product candidates under development for wtATTR as well as other forms of hATTR such as polyneuropathy (PN) and familial amyloid neuropathy (FAP).

Apart from its innovative pipeline, Eidos Therapeutics also boasts a team of experienced professionals who are passionate about making a difference in patients' lives. The company's leadership team includes seasoned executives from top pharmaceutical companies such as Pfizer Inc., Merck & Co., Inc., Genentech Inc., among others.

In conclusion, Eidos Therapeutics is at the forefront of developing novel therapies for diseases caused by transthyretin amyloidosis. With its lead product candidate AG10 showing promising results so far, there is hope that it could be a game-changer for patients suffering from this debilitating condition. As research continues into this area at Eidos therapeutics we can expect more breakthroughs which will help improve patient outcomes significantly over time!